When depression has lingered through medication changes, therapy, and real effort, the next recommendation can feel both hopeful and intimidating. Esketamine treatment is often considered at that point – not as a last resort, but as an evidence-based option for adults with treatment-resistant depression who need a different path forward.
For many patients, the hardest part is not hearing that another treatment exists. It is wondering whether it will actually feel different from everything else they have already tried. That question deserves a clear answer. Esketamine is not simply another daily antidepressant. It works through a different mechanism, is given in a medically supervised setting, and is designed for people whose depression has not improved enough with standard approaches.
What esketamine treatment is
Esketamine is a prescription medication approved by the FDA for adults with treatment-resistant depression, and in some cases for major depressive disorder with acute suicidal thoughts or behaviors when used as part of a broader treatment plan. It is delivered as a nasal spray under medical supervision. The brand name many patients recognize is Spravato.
What makes esketamine different is how quickly it may begin to help some patients compared with traditional antidepressants. While standard medications often target serotonin, norepinephrine, or dopamine over time, esketamine affects glutamate signaling in the brain. Glutamate plays a major role in learning, memory, and neural communication. That difference matters because treatment-resistant depression may require a treatment approach that does not rely on the same pathways as medications that have already fallen short.
That said, faster does not mean instant or universal. Some people notice meaningful changes early, while others improve more gradually over several sessions. Response can vary, and the best outcomes usually come from careful diagnosis, close follow-up, and an overall treatment plan that includes psychiatric support rather than a stand-alone intervention.
Who may benefit from esketamine treatment
Esketamine treatment is generally intended for adults who have tried at least two antidepressants at adequate doses and durations without enough relief. In practice, that often includes people who are still dealing with persistent sadness, loss of interest, exhaustion, hopelessness, poor concentration, sleep disruption, or a level of emotional heaviness that continues to interfere with work, relationships, and daily life.
It may be a good option when depression has been stubborn despite consistent care. It may also be appropriate when symptoms are severe and there is a need to consider a treatment that can begin working on a different timeline than conventional medications.
Still, not every patient with depression is a fit. A proper psychiatric evaluation matters because similar symptoms can appear in bipolar disorder, trauma-related conditions, substance-related disorders, anxiety disorders, and some medical conditions. Safety also needs to be reviewed carefully. Certain cardiovascular issues, uncontrolled high blood pressure, active substance use concerns, or other medical factors may affect whether esketamine is appropriate.
This is why a thorough evaluation should come before treatment planning. The goal is not simply to move quickly. The goal is to make sure the treatment matches the diagnosis and the person receiving it.
How esketamine treatment works in practice
A lot of the anxiety around esketamine comes from not knowing what an appointment actually looks like. The process is more structured than many patients expect, which can be reassuring.
Treatment is administered in the office under supervision. Patients self-administer the nasal spray as directed by the medical team, then remain on site for monitoring for at least two hours. During that observation period, clinicians watch for side effects, check blood pressure, and make sure the patient is stable before discharge. Because of the possibility of temporary sedation, dissociation, or slowed reaction time, patients need someone else to drive them home and should not plan to work, drive, or make major decisions until the next day after a restful night of sleep.
The schedule also tends to be more intensive at first. Treatment often begins with twice-weekly visits for several weeks, then tapers to weekly and later less frequent maintenance visits depending on response. That rhythm can feel demanding, especially for people balancing jobs, caregiving, or long commutes. But it is also part of what makes the treatment safe and clinically useful. Frequent check-ins give the care team a chance to track progress, adjust the plan, and determine whether the treatment is helping in a meaningful way.
What esketamine treatment may feel like
Patients often ask whether they will feel out of control. The better answer is that experiences vary, but treatment is designed to occur in a calm, supervised medical setting where temporary effects can be monitored and managed.
Some people describe feeling detached, lightheaded, dreamy, or less physically grounded during the observation period. Others feel sleepy, mildly nauseated, or emotionally quieter than usual. These effects are generally temporary and fade the same day. For many patients, knowing that these sensations can happen ahead of time makes the experience less unsettling.
What matters most is that any unusual sensations occur in a setting where support is immediately available. A medically supervised environment helps patients feel safer, especially during early sessions when everything is unfamiliar.
Benefits, limits, and realistic expectations
The strongest reason clinicians consider esketamine is simple: it offers a science-backed treatment option for people who have not gotten enough relief from standard antidepressants. For some patients, it can reduce the severity of depressive symptoms, improve functioning, and restore a sense of momentum after months or years of feeling stuck.
But this is also where nuance matters. Esketamine is not a cure, and it is not the right next step for every person with depression. Some patients respond strongly, some partially, and some not enough to justify continuing. Improvement may show up first as getting out of bed more easily, feeling less emotionally flat, or noticing fewer dark thoughts before it becomes a broader return of motivation and pleasure.
It also works best when expectations are grounded. If someone is hoping one or two sessions will erase years of suffering, disappointment is likely. If the expectation is that careful treatment can reduce symptoms and create room for recovery, that is much closer to how meaningful progress usually happens.
Why supervision and follow-up matter
Because esketamine can affect perception, blood pressure, and alertness for a period of time after dosing, supervision is not just a formality. It is part of the treatment itself. The structure allows clinicians to monitor side effects, assess tolerability, and keep the process aligned with best practices.
Just as important, follow-up helps determine whether the treatment is translating into real-world benefit. A patient may report that sessions feel intense but still be unsure whether life outside the office is changing. Regular psychiatric follow-up helps answer that question with more clarity. Are sleep, appetite, concentration, motivation, and suicidal thinking improving? Is the patient functioning better at work or at home? Is maintenance treatment appropriate, or is another strategy needed?
These are the decisions that should be made thoughtfully, not automatically.
Esketamine treatment as part of a broader care plan
The most effective care for treatment-resistant depression is rarely one-dimensional. Esketamine may be an important part of treatment, but it usually works best alongside comprehensive psychiatric care. That can include medication management, therapy, diagnostic clarification, and attention to coexisting conditions such as anxiety, ADHD, trauma, or mood instability.
For patients in Orange County who are considering this option, receiving Spravato in a practice that also understands the broader picture of complex mood disorders can make a real difference. At Brainiac Behavioral Health, Spravato treatment is available in Orange and Anaheim Hills as part of a larger, evidence-based approach to depression care.
That integrated model matters because people are not symptoms on a checklist. They bring treatment histories, family stress, work demands, medical factors, and very understandable fear about trying something new. Good care takes all of that seriously.
Questions worth asking before you start
If you are considering esketamine, a useful first step is not asking whether it is a miracle treatment. It is asking whether it fits your diagnosis, your treatment history, your safety profile, and your goals. You should feel comfortable asking how eligibility is determined, what side effects are most common, how progress will be measured, and what the plan is if you do not respond as hoped.
A good treatment recommendation should feel medically sound and personally understandable. You should know why it is being recommended, what the process involves, and what support will be in place along the way.
Depression can make the future feel very small. The value of advanced treatments like esketamine is that they can reopen options when standard care has not been enough – and sometimes that renewed possibility is where healing begins.